C4 Therapeutics, Inc (CCCC)

$1.54

-0.06

(-3.75%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on C4 Therapeutics, Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.66M → 11.07M (in $), with an average increase of 75.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -35.92M → -27.03M (in $), with an average increase of 32.9% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 155.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 18.7% return, outperforming this stock by 114.0%

Performance

  • $1.52
    $1.64
    $1.54
    downward going graph

    1.3%

    Downside

    Day's Volatility :7.03%

    Upside

    5.81%

    downward going graph
  • $1.23
    $9.41
    $1.54
    downward going graph

    20.13%

    Downside

    52 Weeks Volatility :86.93%

    Upside

    83.63%

    downward going graph

Returns

PeriodC4 Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
-40.07%
-1.3%
0.0%
6 Months
-53.22%
1.2%
0.0%
1 Year
-80.68%
-5.7%
-6.5%
3 Years
-95.29%
17.1%
-6.5%

Highlights

Market Capitalization
73.9M
Book Value
$4.39
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.75
Wall Street Target Price
16.3
Profit Margin
0.0%
Operating Margin TTM
-251.16%
Return On Assets TTM
-22.01%
Return On Equity TTM
-50.51%
Revenue TTM
20.3M
Revenue Per Share TTM
0.42
Quarterly Revenue Growth YOY
63.9%
Gross Profit TTM
-86.7M
EBITDA
-137.9M
Diluted Eps TTM
-2.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.57
EPS Estimate Next Year
-2.51
EPS Estimate Current Quarter
-0.66
EPS Estimate Next Quarter
-0.61

Analyst Recommendation

Buy
    70%Buy
    17%Hold
    11%Sell
Based on 17 Wall street analysts offering stock ratings for C4 Therapeutics, Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
3
4
5
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 958.44%

Current $1.54
Target $16.30

Company Financials

FY18Y/Y Change
Revenue
19.4M
-
Net Income
-15.7M
-
Net Profit Margin
-81.14%
-
FY19Y/Y Change
Revenue
21.4M
↑ 10.42%
Net Income
-34.1M
↑ 117.04%
Net Profit Margin
-159.48%
↓ 78.34%
FY20Y/Y Change
Revenue
33.2M
↑ 55.25%
Net Income
-66.3M
↑ 94.54%
Net Profit Margin
-199.83%
↓ 40.35%
FY21Y/Y Change
Revenue
45.8M
↑ 37.93%
Net Income
-86.0M
↑ 29.7%
Net Profit Margin
-187.92%
↑ 11.91%
FY22Y/Y Change
Revenue
31.1M
↓ 32.08%
Net Income
-126.5M
↑ 47.03%
Net Profit Margin
-406.8%
↓ 218.88%
Q2 FY22Q/Q Change
Revenue
13.8M
↑ 80.74%
Net Income
-27.4M
↓ 13.9%
Net Profit Margin
-198.35%
↑ 218.05%
Q3 FY22Q/Q Change
Revenue
6.8M
↓ 51.18%
Net Income
-31.4M
↑ 14.53%
Net Profit Margin
-465.32%
↓ 266.97%
Q4 FY22Q/Q Change
Revenue
2.9M
↓ 57.74%
Net Income
-36.1M
↑ 14.79%
Net Profit Margin
-1.3K%
↓ 798.77%
Q1 FY23Q/Q Change
Revenue
3.8M
↑ 31.71%
Net Income
-33.9M
↓ 5.93%
Net Profit Margin
-902.85%
↑ 361.24%
Q2 FY23Q/Q Change
Revenue
2.7M
↓ 29.13%
Net Income
-35.9M
↑ 5.85%
Net Profit Margin
-1.3K%
↓ 445.57%
Q3 FY23Q/Q Change
Revenue
11.1M
↑ 315.62%
Net Income
-27.0M
↓ 24.73%
Net Profit Margin
-244.19%
↑ 1104.23%
FY18Y/Y Change
Total Assets
146.5M
-
Total Liabilities
226.2M
-
FY19Y/Y Change
Total Assets
118.3M
↓ 19.27%
Total Liabilities
230.2M
↑ 1.76%
FY20Y/Y Change
Total Assets
400.1M
↑ 238.35%
Total Liabilities
119.3M
↓ 48.16%
FY21Y/Y Change
Total Assets
506.8M
↑ 26.65%
Total Liabilities
117.2M
↓ 1.83%
FY22Y/Y Change
Total Assets
430.8M
↓ 14.98%
Total Liabilities
141.6M
↑ 20.87%
Q2 FY22Q/Q Change
Total Assets
492.5M
↓ 4.46%
Total Liabilities
147.9M
↓ 2.04%
Q3 FY22Q/Q Change
Total Assets
461.4M
↓ 6.3%
Total Liabilities
143.3M
↓ 3.13%
Q4 FY22Q/Q Change
Total Assets
430.8M
↓ 6.63%
Total Liabilities
141.6M
↓ 1.15%
Q1 FY23Q/Q Change
Total Assets
396.0M
↓ 8.08%
Total Liabilities
133.6M
↓ 5.68%
Q2 FY23Q/Q Change
Total Assets
375.0M
↓ 5.31%
Total Liabilities
141.3M
↑ 5.79%
Q3 FY23Q/Q Change
Total Assets
333.0M
↓ 11.2%
Total Liabilities
117.0M
↓ 17.21%
FY18Y/Y Change
Operating Cash Flow
-17.0M
-
Investing Cash Flow
36.9M
-
Financing Cash Flow
2.0M
-
FY19Y/Y Change
Operating Cash Flow
55.6M
↓ 427.51%
Investing Cash Flow
-1.6M
↓ 104.39%
Financing Cash Flow
244.0K
↓ 87.56%
FY20Y/Y Change
Operating Cash Flow
-67.2M
↓ 220.92%
Investing Cash Flow
-190.5M
↑ 11659.57%
Financing Cash Flow
348.9M
↑ 142904.92%
FY21Y/Y Change
Operating Cash Flow
-87.0M
↑ 29.32%
Investing Cash Flow
-189.3M
↓ 0.61%
Financing Cash Flow
171.4M
↓ 50.88%
FY22Y/Y Change
Operating Cash Flow
-105.9M
↑ 21.82%
Investing Cash Flow
58.4M
↓ 130.86%
Financing Cash Flow
1.1M
↓ 99.33%
Q2 FY22Q/Q Change
Operating Cash Flow
-22.2M
↓ 16.55%
Investing Cash Flow
33.2M
↓ 929.87%
Financing Cash Flow
259.0K
↓ 46.04%
Q3 FY22Q/Q Change
Operating Cash Flow
-28.0M
↑ 26.24%
Investing Cash Flow
19.9M
↓ 40.07%
Financing Cash Flow
361.0K
↑ 39.38%

Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics, Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
C4 Therapeutics, Inc
C4 Therapeutics, Inc
-11.6%
-53.22%
-80.68%
-95.29%
-93.72%
Moderna, Inc.
Moderna, Inc.
10.77%
-38.07%
-54.62%
-47.66%
329.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-2.11%
8.61%
7.86%
65.47%
118.58%
Novo Nordisk A/s
Novo Nordisk A/s
-0.67%
27.21%
58.01%
196.12%
339.58%
Seagen, Inc.
Seagen, Inc.
-0.71%
8.98%
75.48%
18.69%
248.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.97%
5.01%
10.57%
53.8%
97.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
C4 Therapeutics, Inc
C4 Therapeutics, Inc
NA
NA
NA
-2.57
-0.51
-0.22
0.0
4.39
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
C4 Therapeutics, Inc
C4 Therapeutics, Inc
Buy
$73.9M
-93.72%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
329.19%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
118.58%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
339.58%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
248.26%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
97.36%
26.52
35.94%

Institutional Holdings

  • Wasatch Advisors Inc.

    12.68%

  • Soleus Capital Management, L.P.

    5.46%

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    4.82%

  • T. Rowe Price Associates, Inc.

    4.44%

  • BlackRock Inc

    4.25%

  • Aquilo Capital Management, LLC

    4.04%

Corporate Announcements

  • C4 Therapeutics, Inc Earnings

    C4 Therapeutics, Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.

Organization
C4 Therapeutics, Inc
Employees
146
CEO
Mr. Andrew J. Hirsch
Industry
Health Technology

Discover More

FAQs